5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine
Related Experiment Video
Updated: Dec 5, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Shu-Yuan Li1, Yi-Qiang Ding2, You-Liang Si2
1International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Abstract:
Multiple endocrine neoplasia type 2 (MEN2) is a neuroendocrine cancer syndrome characterized by medullary thyroid carcinoma, in combination or not with pheochromocytoma, hyperparathyroidism, and extra-endocrine features. MEN2 syndrome includes two clinically distinct forms subtyped as MEN2A and MEN2B. Nearly all MEN2 cases are caused by germline mutations of the RET proto-oncogene. In this review, we propose "5P" strategies for management of MEN2: prevention, prediction, personalization, psychological support, and participation, which could effectively improve clinical outcomes of patients. Based on RET mutations, MEN2 could be prevented through prenatal diagnosis or preimplantation genetic testing. Identification of pathogenic mutations in RET can enable early diagnosis of MEN2. Combining RET mutation testing with measurement of serum calcitonin, plasma or urinary metanephrine/normetanephrine, and serum parathyroid hormone levels could allow risk stratification and accurately prediction of MEN2 progression, thus facilitating implementation of personalized precision treatments to increase disease-free survival and overall survival. Furthermore, increased awareness of MEN2 is needed, which requires participation of physicians, patients, family members, and related organizations. Psychological support is also important for patients with MEN2 to promote comprehensive management of MEN2 symptoms. The "5P" strategies for management of MEN2 represent a typical clinical example of precision medicine. These strategies could effectively improve the health of MEN2 patient, and avoid adverse outcomes, including death and major morbidity, from MEN2.
Insights
Multiple endocrine neoplasia type 2 (MEN2) management can be improved with "5P" strategies: prevention, prediction, personalization, psychological support, and participation. These approaches, guided by RET proto-oncogene mutations, enhance patient outcomes and survival for this neuroendocrine cancer syndrome.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Background:
- Multiple endocrine neoplasia type 2 (MEN2) is a hereditary neuroendocrine cancer syndrome.
- MEN2 is primarily caused by germline mutations in the RET proto-oncogene.
- MEN2 presents in two main forms: MEN2A and MEN2B, often involving medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism.
Purpose of the Study:
- To propose a comprehensive
- 5P
- management framework for MEN2.
- To highlight the role of RET proto-oncogene mutations in MEN2 management.
- To emphasize the integration of precision medicine strategies for improved patient outcomes.
Main Methods:
- Review of existing literature and clinical guidelines for MEN2 management.
- Focus on RET proto-oncogene mutation analysis for diagnosis and risk stratification.
- Integration of diagnostic markers (calcitonin, metanephrine/normetanephrine, parathyroid hormone) for prediction.
- Incorporation of genetic testing (prenatal diagnosis, preimplantation genetic testing) for prevention.
Main Results:
- The
- 5P
- strategies (prevention, prediction, personalization, psychological support, participation) offer a structured approach to MEN2 management.
- RET mutation testing enables early diagnosis, risk stratification, and personalized treatment.
- Multidisciplinary participation and psychological support are crucial for comprehensive care.
Conclusions:
- The proposed
- 5P
- strategies represent a precision medicine model for MEN2.
- Effective implementation can significantly improve disease-free survival and overall survival.
- These strategies aim to prevent adverse outcomes, including mortality and major morbidity, associated with MEN2.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers

